Moderna, Inc.

NASDAQ:MRNA

Biotechnology

Healthcare
$196.79 +4.01%

+$2.48 today

Market cap
$79.63B
Beta
1.03
P/E (TTM)
-7.9
EPS (TTM)
-$8.09
52W Low $22.28High $67.74

Volume 6.91M

Average 6.53M

MRNA Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Moderna, Inc.NASDAQ: MRNA

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization growth accelerates

Q3 FY2026 depreciation & amortization of $68M rose 30.8% year over year, ahead of the +23.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 7.9% from the prior quarter. Over 3 fiscal years it compounded at -14.8% a year.

Context

  • Depreciation & amortization amounted to 11.1% of revenue in FY2025, up 5.2 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +30.8% holds above the trailing-twelve-month pace of +23.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$68M+7.9% QoQ
Last fiscal yearDec 2025
$215M+13.8% YoY
LTMSep 2026
$257M+23.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+30.8%——
1 year+13.8%——
3-year CAGR-14.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
215M USD
Year-over-year change
+13.8%
4-year CAGR
-1.9%

Depreciation & Amortization vs competitors

How MRNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +23.6% is the 5th highest of 10, against a peer median of -3.0%.
  • Depreciation & amortization amounts to 10.2% of revenue for MRNA, versus a peer median of 10.3%.
MRNA Competitors
Depreciation & Amortization for MRNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PFEPfizer Inc.LTM Jun 2026$6.58B USD-3.0%+9.2%10.3%
GSKGSK plcLTM Jun 2026£2.21B GBP-34.0%+2.5%6.7%
BNTXBioNTech SELTM Jun 2026€676.85M EUR+122.9%+43.9%25.6%
MRNAModerna, Inc.LTM Sep 2026$257M USD+23.6%-14.8%10.2%
PCVXVaxcyte, Inc.LTM Jun 2026$26.8M USD+40.0%+38.0%—
VALNValneva SELTM Mar 2026€25.21M EUR+138.6%+1.1%16.1%
NVAXNovavax, Inc.LTM Mar 2026$22.34M USD-50.0%-1.7%3.7%
VIRVir Biotechnology, Inc.LTM Mar 2026$18.23M USD+41.3%+46.1%27.8%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$2.99M USD-3.9%-18.4%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$2.88M USD-16.2%+25.6%6.4%
Peer median (excluding MRNA) —-3.0%+9.2%10.3%

Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income12.2B8.36B(4.71B)(3.56B)(2.82B)
Depreciation & Amortization232M348M621M189M215M
Deferred Income Tax(318M)(559M)828M00
Stock-Based Compensation142M226M305M429M483M
Change in Working Capital1.31B(3.46B)(139M)(78M)254M
Accounts Receivables(1.78B)1.79B493M534M156M
Inventory(1.39B)492M747M83M(34M)
Accounts Payables204M240M13M(69M)(92M)
Other Working Capital4.28B(5.98B)(1.39B)(626M)224M
Other Non-Cash Items54M59M(19M)17M(3M)
Operating Cash Flow13.62B4.98B(3.12B)(3B)(1.87B)
Capital Expenditures(284M)(400M)(707M)(1.05B)(192M)
Acquisitions (Net)00(85M)00
Purchases of Investments(12.65B)(11.44B)(3.78B)(6.53B)(5.77B)
Sales of Investments4.44B6.7B8.78B9.53B7.92B
Other Investing Activities(30M)(40M)00(10M)
Investing Cash Flow(8.52B)(5.18B)4.21B1.95B1.95B
Debt Repayment(140M)(184M)(270M)(10M)539M
Common Stock Issued124M65M46M66M35M
Common Stock Repurchased(857M)(3.33B)(1.15B)00
Dividends Paid00000
Other Financing Activities000019M
Financing Cash Flow(873M)(3.45B)(1.38B)56M593M
Effect of Forex Changes00002M
Net Change in Cash4.22B(3.64B)(289M)(999M)668M
Free Cash Flow13.34B4.58B(3.83B)(4.06B)(2.07B)

Moderna, Inc.

NASDAQ:MRNA

Intrinsic Alpha fair value

Locked

Current Price

$196.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.